- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.06. | Revelation Biosciences, Inc.: Revelation Biosciences Expands Acute Kidney Injury Advisory Board | 182 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 11.05. | Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders | 576 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 08.05. | Revelation Biosciences GAAP EPS of -$2.71 | 2 | Seeking Alpha | ||
| 07.05. | Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 | 358 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 07.05. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.04. | REVELATION BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 06.04. | Revelation Biosciences forms advisory board for AKI trial | 3 | Investing.com | ||
| 06.04. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board | 358 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 30.03. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study | 292 | ACCESS Newswire | - A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Newswire... ► Artikel lesen | |
| 24.03. | Revelation Biosciences, Inc.: REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 206 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 19.03. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.03. | Revelation Biosciences, Inc.: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 372 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 27.02. | Revelation Biosciences reports FY results | 2 | Seeking Alpha | ||
| 26.02. | Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 | 405 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 29.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.01. | Revelation Biosciences kündigt Reverse-Split im Verhältnis 1:4 an | 3 | Investing.com Deutsch | ||
| 26.01. | Revelation Biosciences to implement 1-for-4 reverse stock split | 3 | Investing.com | ||
| 26.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 | 737 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 8,050 | +2,29 % | Novavax-Aktionäre billigen auf Hauptversammlung wichtige Anträge | ||
| PALATIN TECHNOLOGIES | 11,610 | -1,36 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,200 | +5,82 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,332 | -3,49 % | NurExone stärkt globalen Patentschutz für seine Exosomen-Plattform | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,159 | -0,17 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 140,40 | -0,74 % | Stifel reiterates Neurocrine Bio stock rating on Vykat potential | ||
| REDHILL BIOPHARMA | 0,870 | +3,57 % | RedHill Biopharma closes $6 million private placement | ||
| ONCO-INNOVATIONS | 0,420 | 0,00 % | Onco-Innovations schließt Projekt mit Kuano ab und nutzt dessen quantenbasierte Plattform, um Erkenntnisse für die Optimierung der PNKP-Inhibitor-Technologie bereitzustellen | Vancouver, Kanada - 16. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") freut sich, im Anschluss an seine... ► Artikel lesen | |
| NOVOCURE | 11,855 | +0,13 % | Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start... ► Artikel lesen | |
| PHARMING | 1,170 | +2,86 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,900 | +1,71 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| REVOLUTION MEDICINES | 149,90 | +3,34 % | Das geheime Verfahren das Krebszellen sterben lässt: Was Revolution Medicines und Merck & Co. von Vidac Pharma lernen müssen | Hier kann man ohne Übertreibung von einer Patent-Superklippe sprechen: Satte 236 Mrd. USD drohende jährliche Umsatzverluste zwingen die biopharmazeutische Industrie dazu, neue Wege zu gehen. Pharma-Riesen... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 3,120 | +4,00 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| PALISADE BIO | 1,960 | +6,52 % | Palisade Bio, Inc.: Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors | Board strengthened with extensive biotechnology leadership, strategic transactions and capital markets expertise Company continues to build on PALI-2108 clinical progress as it advances toward Phase... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,939 | +2,42 % | Stocks in Play: Oncolytics Biotech Inc |
REVELATION BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,020 (-1,90 %) liegt der Kurs bei 1,030 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.